Apogee Therapeutics Inc (APGE) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days...

Apogee Therapeutics Announces Agenda for Virtual R&D Day

SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq:...

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq:...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results

Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq:...